Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

Objective: The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Terrés, Carlos, Graefenhain de Codes, Ruth, Rubio-Rodríguez, Darío, Evers, Thomas, Grau Cerrato, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2016
Materias:
Cardiovascular Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471359/
https://www.ncbi.nlm.nih.gov/pubmed/37663009
http://dx.doi.org/10.36469/9823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471359/
https://www.ncbi.nlm.nih.gov/pubmed/37663009
http://dx.doi.org/10.36469/9823

Ejemplares similares